Kvantify Secures €7M Funding to Scale Quantum Drug Discovery Platform
Kvantify announced the second close of its funding round, bringing total capital raised to €7 million ($8.1 million) from the European Innovation Council Fund and Delphinus Venture Capital. The funding will accelerate the commercialization of its hybrid quantum‑classical software stack, Qrunch, for molecular simulation and drug design. The round highlights European deep‑tech investment in quantum drug discovery.
Teva Secures $400M Funding From Blackstone Life Sciences
Teva Pharmaceutical announced a $400 million financing from Blackstone Life Sciences to advance duvakitug, a Sanofi‑partnered TL1A blocker for inflammatory bowel disease. The investment will be disbursed over four years, with Blackstone receiving regulatory milestones and low‑single‑digit royalties on worldwide sales.
Antiverse Raises $9.3M Series A Led by Soulmates Ventures
Antiverse, an AI-driven antibody design company, announced a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund. The funding brings total capital to over $20 million and will...
Scholar Rock Secures $550M Debt Facility From Blue Owl Capital
Scholar Rock Holding Corp announced it has secured a new debt facility of up to $550 million from Blue Owl Capital. The facility includes $100M drawn to refinance existing debt, $100M available for draw in Q1, $150M contingent on FDA...
Gyre Therapeutics to Acquire Cullgen in $300M All‑Stock Deal
Gyre Therapeutics announced an agreement to acquire Cullgen in an all‑stock transaction valued at approximately $300 million, making Cullgen a wholly‑owned subsidiary upon completion in Q2 2026. The combined biopharma company will integrate US and China capabilities across discovery, manufacturing and commercialization,...
Alveus Therapeutics Secures $37M Series A Extension Funding
Alveus Therapeutics Inc., a clinical‑stage biotech firm, closed a $37 million Series A extension round. The round was led by Jeito Capital and Novo Holdings, with participation from New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience...
Candid to Acquire Rallybio in Reverse Merger, Taking Company Public
Candid Therapeutics announced a reverse merger with Rallybio, creating a publicly traded company under the Candid name and ticker CDRX. The boards of both companies approved the transaction, which is expected to close in mid‑2026. The deal includes a $505 million...
Kairos Pharma Signs Binding Agreement to Acquire Exclusive Worldwide Rights to CL‑273 From Celyn Therapeutics
Kairos Pharma announced it has signed a binding agreement to acquire the exclusive worldwide rights to the AI‑designed pan‑EGFR inhibitor CL‑273 from Celyn Therapeutics, a biotech backed by OrbiMed and Torrey Pines Investment. The acquisition expands Kairos’s oncology pipeline and...
Zura Bio Raises $144M in Public Offering to Advance Autoimmune Drug Pipeline
Zura Bio, a clinical‑stage biotechnology firm, completed a $144 million public offering of Class A ordinary shares and pre‑funded warrants, with underwriters fully exercising their option for additional shares. The proceeds will fund Phase 2 trials for its lead candidate tibulizumab and support...
Asahi Kasei to Acquire German Biotech Aicuris for €780M
Japanese drugmaker Asahi Kasei announced it will acquire German biotech Aicuris for €780 million, gaining its antiviral therapy pritelivir targeting HSV. The deal expands Asahi Kasei's anti‑infectives portfolio and supports its goal of reaching JPY 300 billion in pharma sales by 2030.
Tamarind Bio Raises $12M Series A to Build AI Operating System for Biotech
Biotech AI infrastructure startup Tamarind Bio announced a $12 million Series A round led by Dimension Capital, bringing total funding to $13.6 million. The capital will fund headcount expansion and further development of its AI operating system for drug discovery labs.
Natera Acquires Foresight Diagnostics to Boost Ultra‑Sensitive MRD Testing
Natera announced the acquisition of Foresight Diagnostics during its Q4 2025 earnings call on Feb. 26, 2026. The deal adds Foresight's phased‑variant technology to Natera's Signatera platform, enabling detection below one fragment per 10 million normal copies. Financial terms were not...
GSK to Acquire 35Pharma for Under $1B
GlaxoSmithKline (GSK) announced the acquisition of privately held 35Pharma, a developer of a pulmonary arterial hypertension drug. The cash deal is valued at just under $1 billion, expanding GSK’s pipeline in respiratory and immunology.
Brainomix Raises £4.8m in Series C Extension, Bringing Total to £18.8m
Oxford‑based AI imaging firm Brainomix announced a £4.8 million extension to its Series C round, taking the total to £18.8 million. The new funding, led by existing investors Parkwalk Advisors and Hostplus (via the IP Group Hostplus Innovation Fund) and joined by new...
Centauri Therapeutics Raises £30m Series A Round
Centauri Therapeutics, a Cheshire‑based biotech, announced a £30 million Series A funding round to advance its antimicrobial immunotherapy programme, including a £6 million investment from AMR Action Fund. The capital will support the completion of Phase I trials for its lead candidate...
Beam Therapeutics Secures $500M Strategic Financing From Sixth Street
Beam Therapeutics announced a $500 million strategic financing agreement with Sixth Street to fund the potential launch of its sickle cell disease therapy and advance its BEAM‑304 program for phenylketonuria. The financing will support development of the gene‑editing platform and...
Slate Medicines Secures $130M Series A Funding Led by RA Capital, Forbion and Foresite Capital
Slate Medicines, a North Carolina‑based biotech startup, announced a $130 million Series A round to fund development of its PACAP‑blocking migraine antibody SLTE‑1009. The round was led by RA Capital, Forbion and Foresite Capital, with participation from an undisclosed biotech investor. The...
Guardant Health Acquires MetaSight Diagnostics for $59M Upfront
Guardant Health announced the acquisition of MetaSight Diagnostics for $59 million in upfront cash, with up to $90 million in additional contingent payments tied to commercial performance and regulatory approvals. The deal expands Guardant’s multi‑disease detection pipeline beyond oncology, adding MetaSight’s mass‑spectrometry...
Gilead Sciences to Acquire Arcellx for up to $7.8B
Gilead Sciences announced it will acquire biotech Arcellx in a cash deal valued at up to $7.8 billion, paying $115 per share plus a contingent $5 per share based on future sales. The acquisition aims to strengthen Gilead's cancer drug pipeline,...
Candel Therapeutics Secures $100M Royalty Funding From RTW Investments
Candel Therapeutics announced a $100 million royalty financing agreement with RTW Investments to support the launch of its gene therapy Aglatimagene Besadenovec for localized prostate cancer. The deal grants RTW a capped, tiered royalty on U.S. net sales, contingent on...
Resurrect Bio Secures $8.1M in Series A Initial Close
Resurrect Bio announced an $8.1 million initial close of its Series A financing round, marking the first tranche of capital for the biotech startup. The round aims to fund the company's next phase of research and development.
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Altesa BioSciences Secures $75M Series B Funding
Altesa BioSciences announced a $75 million Series B financing round, bolstering its pipeline in the biotech sector. The new capital will support the company's research and development initiatives and accelerate growth.
Sensei Biotherapeutics Acquires Faeth Therapeutics in Stock-for-Stock Deal, Raises $200M
Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics in a stock-for-stock transaction, consolidating the two biotech firms. Concurrently, Sensei raised $200 million in a private placement to fund the development of PIKTOR, its multi-node PI3K/AKT/mTOR inhibitor. The acquisition price was...
Peptris Raises ₹70 Crore to Scale AI-Led Drug Discovery Pipeline
Peptris, an AI-driven drug discovery startup, announced a fresh funding round of ₹70 crore to expand its pipeline and accelerate preclinical programs. The capital will be used to scale its AI-led platform and advance its drug discovery efforts. The raise...
Gilead to Acquire Genhouse in $1.5B+ Deal to Accelerate Synthetic Lethality
Gilead Sciences announced a deal to acquire Genhouse for over $1.5 billion, aiming to strengthen its synthetic lethality oncology pipeline. The acquisition brings Genhouse’s portfolio of synthetic lethality drug candidates and technology into Gilead’s pipeline, underscoring its commitment to precision oncology.
Korsana Raises $150M in Series A to Develop Next‑gen Alzheimer’s Antibody
Korsana, a biotech focused on Alzheimer’s disease, announced a $150 million Series A funding round to advance its next‑generation amyloid‑targeting antibody. The capital will fund clinical development and expansion of its pipeline. Investor identities were not disclosed.
Unnatural Products Secures $1.8B Cardio Pact with Novartis
Biotech firm Unnatural Products announced a $1.8 billion partnership with pharmaceutical giant Novartis to develop cardiovascular therapies. The agreement includes a corporate investment from Novartis, marking a significant funding boost for Unnatural Products.
Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab
Eli Lilly announced it will pay $100 million to CSL Limited for the rights to the IL‑6‑blocking antibody clazakizumab, with CSL retaining rights for cardiovascular prevention in end‑stage kidney disease patients. The deal includes an upfront payment and potential milestone and...
Intrinsic Foundries Secures Rs 12 Cr Seed Funding Led by Transition VC
Intrinsic Foundries, a carbon‑to‑value biomanufacturing startup, announced a seed round of Rs 12 crore (≈$1.4 million) led by Transition VC. The capital will fund industrial pilots, research expansion, IP filing, and the creation of a US entity to support global market development.
BioReact Secures Undisclosed Investment From University of Tulsa and Hurricane Ventures
BioReact, an Indianapolis‑based AI and analytics platform for bioprocess development, announced an undisclosed investment from the University of Tulsa and Hurricane Ventures. The funding will be used to accelerate go‑to‑market efforts and expand product capabilities. The announcement was made on...
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
AMPLY Discovery Secures Strategic Investment From Keeps Biomed
AMPLY Discovery, an AI‑driven drug discovery platform based in Belfast, has received a strategic investment from Keeps Biomed, a subsidiary of South Korean biotech Keeps Biopharma. The undisclosed amount will be used to advance oncology research, expand its drug discovery...
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Aerska Raises $39M in Back-to-Back Financing to Advance Brain Gene‑silencing Therapies
Irish‑British biotech Aerska, developing brain‑shuttle technology to deliver siRNA across the blood‑brain barrier, announced a $39 million financing round. The new funding follows a prior raise just four months earlier and will support development of treatments for neurological diseases. Investors were...
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Galux Secures $29M Series B Funding Led by Yuanta
South Korean biotech Galux Inc., which uses generative AI for protein and antibody design, announced a $29 million Series B financing led by Yuanta. The fresh capital will support scaling of its AI‑driven biologics platform and recent collaboration with Boehringer Ingelheim. The...
Java Capital Launches Rs 400 Cr Deep‑tech Seed‑stage Fund
Java Capital announced the launch of a Rs 400 crore deep‑tech fund aimed at seed‑stage startups across sectors such as semiconductors, aerospace, defence, cybersecurity, AI infrastructure, robotics, advanced manufacturing, energy, climate tech, and synthetic biology. The fund includes a Rs 150 crore greenshoe option...
Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion
Eli Lilly announced it will acquire biotech firm Orna Therapeutics for up to $2.4 billion. Orna's in vivo CAR-T and circular RNA technology targets autoimmune diseases, expanding Lilly's cell-therapy pipeline.
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
BeHuman Raises $4M Seed Round to Advance Early Cancer Detection
beHuman, a physician-led preventive care platform focused on early cancer detection for underserved populations, announced a $4 million seed round. The funding will support the company's efforts to expand its services and improve early detection capabilities.
SonoVascular Secures $6M Series A Funding Led by Harbright Ventures
SonoVascular, a clinical‑stage medical‑device company, announced the first close of its $6 million Series A preferred stock financing, led by Harbright Ventures. The capital will fund FDA approval for a pivotal peripheral venous study and a first‑in‑human trial for pulmonary embolism treatment....
Novartis to Acquire Avidity Biosciences in $12B Takeover
Swiss pharma giant Novartis announced it will acquire RNA‑drug developer Avidity Biosciences for $12 billion, with the transaction expected to close in the next few months. The deal is part of Novartis' strategy to bolster its pipeline amid significant patent expiries,...
Imbed Biosciences Secures Undisclosed Investment From BioLab Holdings
Imbed Biosciences, a synthetic antimicrobial and tissue‑regeneration solutions company, announced an undisclosed investment from BioLab Holdings to accelerate development of its SAM Antimicrobial Technology platform for wound‑care. The funding will support product development and commercialization efforts. The deal was reported...
PrimeGen US to Merge with DT Cloud Star Acquisition Corp in $1.5B SPAC Deal
California-based biotech PrimeGen US announced a merger with SPAC DT Cloud Star Acquisition Corporation, valuing PrimeGen at approximately $1.5 billion in equity. The transaction, disclosed in a February 4 SEC filing, is expected to close in the second half of 2026 pending...
